Joonas Lehto, Markus Malmberg, Fausto Biancari, Juha Hartikainen, Leo Ihlberg, Fredrik Yannopoulos, Teemu Riekkinen, Anna Nissfolk, Samuli Salmi, Maunu Nissinen, Juhani Airaksinen, Tuomo Nieminen & Tuomas Kiviniemi (2018) Occurrence and Classification of Cerebrovascular Events after Isolated Bioprosthetic Surgical Aortic Valve Replacement: A Competing Risk Analysis of the CAREAVR Study, Structural Heart, 2:2, 157-163, DOI: 10.1080/24748706.2017.1419327
Occurrence and classification of cerebrovascular events after isolated bioprosthetic surgical aortic valve replacement : a competing risk analysis of the CAREAVR study
|Author:||Lehto, Joonas1; Malmberg, Markus1; Biancari, Fausto1,2;|
1Heart Center, Turku University Hospital and University of Turku, Turku, Finland
2Department of Surgery, Oulu University Hospital, Oulu, Finland
3Heart Center, Kuopio University Hospital, Kuopio, Finland
4Department of Cardiothoracic Surgery, Helsinki University Hospital, Helsinki, Finland
5Department of Internal Medicine, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
6Department of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland
|Online Access:||PDF Full Text (PDF, 1.8 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe201901242968
|Publish Date:|| 2019-01-24
Background: The long-term incidence of stroke and the proportion of cardioembolic events after bioprosthetic surgical aortic valve replacement (SAVR) remain largely unknown.
Methods: The CAREAVR study sought to assess the rate of stroke and transient ischemic attack (TIA) in patients who underwent isolated surgical aortic valve replacement with a bioprosthesis at four Finnish university hospitals between 2002 and 2014. Data was collected retrospectively and included 721 patients. Median follow-up time was 4.8 [3.0–7.0] years.
Results: At 5 years, freedom from stroke was 89.0%, from TIA 94.1%, and from stroke and TIA 83.7%. The median time between index procedure and stroke or TIA was 1.7 years [29 days–3.9 years]. Stroke was of cardioembolic origin in 44.4% of patients. In multivariable competing risk analysis, increased age (HR 1.03, 95%CI 1.00–1.06, p = 0.022), previous stroke or TIA (HR 1.75, 95%CI 1.14–2.70, p = 0.010), New York Heart Association (NYHA) class III or more (HR 1.51, 95%CI 1.01–2.24, p = 0.044) and insulin treatment at discharge (HR 1.20, 95%CI 1.09–3.64, p = 0.024) were independent predictors of stroke or TIA. Cerebrovascular events occurred in 47.2% of patients with ongoing anticoagulation therapy.
Conclusion: In this study, the incidence of stroke in the early postoperative period after bioprosthetic SAVR was higher than previously documented. Almost half of strokes were of cardioembolic etiology. These findings highlight the need for the better prevention strategies for cardioembolic events after bioprosthetic SAVR.
|Pages:||157 - 163|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3126 Surgery, anesthesiology, intensive care, radiology
© 2018 The authors. Published with license by Taylor & Francis. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.